Table 3 Cox proportional hazards model predicting time to remission
Baseline characteristics | Univariate | Multivariable | ||
|---|---|---|---|---|
HR (95% CI) | p-value | HR (95% CI) | p-value | |
Sociodemographic | ||||
Female gender | 0.71 (0.60–0.84) | <.0001 | 0.87 (0.70–1.09) | 0.2256 |
Post-secondary education | 1.26 (1.08–1.47) | 0.0039 | 1.04 (0.87–0.70) | 0.6744 |
Ever smoked | 0.87 (0.75–1.02) | 0.076 | 0.93 (0.77–1.12) | 0.4269 |
RA family history | 0.89 (0.74–1.07) | 0.2176 | 0.87 (0.70–1.70) | 0.1817 |
Disease characteristics | ||||
Positive rheumatoid factor | 1.01 (0.85–1.19) | 0.9182 | 0.94 (0.78–1.14) | 0.5381 |
HAQ-DI | 0.62 (0.55–0.69) | <.0001 | 0.71 (0.61–0.84) | <.0001 |
Morning stiffness (>30 min) | 0.71 (0.61–0.83) | <.0001 | 0.89 (0.73–1.08) | 0.2366 |
Joint erosion | 0.94 (0.77–1.14) | 0.5224 | 0.87 (0.70–1.08) | 0.1954 |
DAS28 | 0.77 (0.72–0.82) | <.0001 | 0.88 (0.80–0.96) | 0.0048 |
Extra-articular features | 0.95 (0.78–1.14) | 0.5534 | ||
Number of comorbidities | 0.83 (0.77–0.88) | <.0001 | 0.88 (0.81–0.95) | 0.0022 |
Osteoarthritis | 0.93 (0.78–1.12) | 0.4497 | ||
Treatment | ||||
Oral glucocorticoid | 1.06 (0.86–1.30) | 0.5800 | ||
Biologic or JAK inhibitor (time variant) | 0.86 (0.71–1.03) | 0.09 | 1.53 (0.63–3.69) | 0.3485 |
LORA | 0.83 (0.71–0.97) | 0.0194 | 1.10 (0.90–1.34) | 0.3593 |